| First Author | Arbeeny CM | Year | 1995 |
| Journal | Am J Physiol | Volume | 268 |
| Issue | 4 Pt 1 | Pages | E678-84 |
| PubMed ID | 7733267 | Mgi Jnum | J:24491 |
| Mgi Id | MGI:73317 | Doi | 10.1152/ajpendo.1995.268.4.E678 |
| Citation | Arbeeny CM, et al. (1995) Metabolic alterations associated with the antidiabetic effect of beta 3-adrenergic receptor agonists in obese mice. Am J Physiol 268(4 Pt 1):E678-84 |
| abstractText | Treatment of obese (ob/ob) mice with the beta 3-adrenergic receptor (beta 3-AR) agonist BRL-35135 (1 mg.kg body wt-1.day-1 for 20 days) normalized plasma glucose levels and significantly decreased plasma insulin and nonesterified fatty acid levels. The time frame for the hypoglycemic effect, which reached a maximum after 10 days of treatment, paralleled an increase in brown adipose tissue DNA and protein content. The basal level of mRNA for the beta 3-AR and mitochondrial uncoupling protein was found to be markedly decreased in the ob/ob animals relative to the lean group. Chronic treatment of ob/ob mice for 20 days resulted in a twofold increase in beta 3-AR mRNA and a fivefold increase in uncoupling protein mRNA in brown adipose tissue relative to the placebo group. These findings indicate that chronic treatment of ob/ob animals with a beta 3-AR agonist results in proliferation of brown adipose tissue, with an upregulation of the beta 3-AR, which is associated with a decrease in plasma glucose, insulin, and nonesterified fatty acid levels. |
